Azacitidine successfully maintained the second remission in an infant with KMT2A‐rearranged acute lymphoblastic leukemia who relapsed after unrelated cord blood transplantation
Pediatric Blood & Cancer2017Vol. 64(12)
Citations Over TimeTop 12% of 2017 papers
Ikue Chijimatsu, Yusuke Imanaka, Daisuke Tomizawa, Mariko Eguchi, Shiho Nishimura, Shuhei Karakawa, Mizuka Miki, Kazuko Hamamoto, Naoto Fujita
Abstract
The outcome for infants with KMT2A (MLL)-rearranged acute lymphoblastic leukemia (MLL-r ALL) is dismal despite intensive therapy, including hematopoietic stem cell transplantation (HSCT). Epigenetic dysregulation is considered a key driver of MLL-r leukemogenesis, which theoretically supports the use of epigenetic modifiers as a treatment option. We report an infant MLL-r ALL case with post-HSCT relapse. After achieving a second remission, which was maintained for 10 months using only the DNA methyltransferase inhibitor, azacitidine, the patient successfully received the second HSCT. This report describes the clinical effectiveness of azacitidine for the treatment of infant MLL-r ALL.
Related Papers
- → Sustained remission with azacitidine monotherapy and an aberrant precursor B‐lymphoblast population in juvenile myelomonocytic leukemia(2019)12 cited
- → BH3 mimetics and azacitidine show synergistic effects on juvenile myelomonocytic leukemia(2023)4 cited
- → Azacitidine as a bridge to transplantation in juvenile myelomonocytic leukemia(2022)1 cited
- → Analyzing the therapeutic efficacy of navitoclax and MCL-1 inhibitors in juvenile myelomonyctic leukemia(2019)
- → BH3 mimetics and azacitidine show synergistic effects on juvenile myelomonocytic leukemia(2023)